| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Yu Du | |
| Yongchang Wei | |||
| P2860 | cites work | The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis | Q21260393 |
| Immunology. A perfect mismatch | Q77768910 | ||
| Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer | Q78386151 | ||
| Tumor-associated macrophage (TAM) infiltration in gastric cancer | Q79357794 | ||
| Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components | Q80486786 | ||
| Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation | Q80805671 | ||
| Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma | Q80945328 | ||
| Decrease in intrahepatic CD56+ lymphocytes in gastric and colorectal cancer patients with liver metastases | Q82533270 | ||
| Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor | Q84959352 | ||
| Molecular insight into targeting the NK cell immune response to cancer | Q88169958 | ||
| Natural killers join the fight against cancer | Q88219719 | ||
| Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 | Q90568939 | ||
| Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells | Q26751020 | ||
| Immunotherapy in gastric cancer | Q27010472 | ||
| Global cancer statistics, 2012 | Q27860501 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| Comprehensive molecular characterization of gastric adenocarcinoma | Q28244985 | ||
| Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer | Q28266580 | ||
| Functions of natural killer cells | Q29614300 | ||
| Innate or adaptive immunity? The example of natural killer cells | Q29615106 | ||
| NK cell recognition | Q29615107 | ||
| Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants | Q29619458 | ||
| Macrophage activation and polarization: nomenclature and experimental guidelines | Q29620642 | ||
| The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans | Q33292180 | ||
| Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress | Q33593871 | ||
| Natural killer cell cytotoxicity and immunosuppressive cytokines (IL-10, TGF-beta1) in patients with gastric cancer | Q33813425 | ||
| NK cell-based immunotherapy for malignant diseases | Q33827433 | ||
| Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy | Q33875615 | ||
| Oncology meets immunology: the cancer-immunity cycle | Q34037625 | ||
| Tumor necrosis factor signaling. | Q34185821 | ||
| Human natural killer cell receptors and co-receptors | Q34341459 | ||
| Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. | Q34581796 | ||
| Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells | Q34605718 | ||
| Function and subsets of dendritic cells and natural killer cells were decreased in gastric cancer. | Q34733278 | ||
| NKG2D ligands: key targets of the immune response. | Q34792486 | ||
| Activation of STAT3 in human gastric cancer cells via interleukin (IL)-6-type cytokine signaling correlates with clinical implications | Q35014555 | ||
| Cytokine therapy reverses NK cell anergy in MHC-deficient tumors | Q35140125 | ||
| Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients | Q35157421 | ||
| Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells | Q35847820 | ||
| Bisphosphonate-induced differential modulation of immune cell function in gingiva and bone marrow in vivo: role in osteoclast-mediated NK cell activation | Q36299558 | ||
| Constitutive Cytokine mRNAs Mark Natural Killer (NK) and NK T Cells Poised for Rapid Effector Function | Q36371748 | ||
| Regulatory T cells, tumour immunity and immunotherapy | Q36430144 | ||
| Antitumor effects of vaccine consisting of dendritic cells pulsed with tumor RNA from gastric cancer | Q36474090 | ||
| Gastric cancer cells inhibit natural killer cell proliferation and induce apoptosis via prostaglandin E2. | Q36711029 | ||
| Gastric cancer-derived heat shock protein-gp96 peptide complex enhances dendritic cell activation | Q40135301 | ||
| Intravenous administration of MIP-1alpha with intra-tumor injection of P. acnes shows potent anti-tumor effect | Q40139686 | ||
| Killer cell Ig-like receptors ligand-mismatched, alloreactive natural killer cells lyse primary solid tumors | Q40262316 | ||
| Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of NK cell-mediated cytotoxicity | Q40445064 | ||
| Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability | Q40503160 | ||
| ICAM-2 gene therapy for peritoneal dissemination of scirrhous gastric carcinoma | Q40532762 | ||
| Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients | Q40581214 | ||
| Different regulation of PKC isoenzymes and MAPK by PSK and IL-2 in the proliferative and cytotoxic activities of the NKL human natural killer cell line. | Q40676251 | ||
| Human gastric carcinoma transduced with theIL-2 gene: Increased sensitivity to immune effector cellsin vitro andin vivo | Q41100236 | ||
| Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma | Q41298062 | ||
| Natural Killer Cells: Angels and Devils for Immunotherapy | Q41661175 | ||
| Intracellular poly(I:C) initiated gastric adenocarcinoma cell apoptosis and subsequently ameliorated NK cell functions | Q41863836 | ||
| Immunology: Natural killer cells remember | Q44002588 | ||
| Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. | Q44783161 | ||
| Natural killer cell signaling pathways | Q45165250 | ||
| SnapShot: Immune Checkpoint Inhibitors. | Q45939025 | ||
| Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers | Q47165141 | ||
| Expression levels of UL16 binding protein 1 and natural killer group 2 member D affect overall survival in patients with gastric cancer following gastrectomy. | Q49386911 | ||
| Human Leukocyte Antigen-G Inhibits the Anti-Tumor Effect of Natural Killer Cells via Immunoglobulin-Like Transcript 2 in Gastric Cancer | Q49972194 | ||
| Chimeric antigen receptors in different cell types: new vehicles join the race | Q50025590 | ||
| Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. | Q50920053 | ||
| Increased apoptosis and elevated Fas expression in circulating natural killer cells in gastric cancer patients. | Q53132585 | ||
| Natural killers: cataloging immune cells for immunotherapy. | Q53593950 | ||
| B7-H6 protein expression has no prognostic significance in human gastric carcinoma. | Q54586743 | ||
| Interleukin-15 suppresses gastric cancer liver metastases by enhancing natural killer cell activity in a murine model | Q58779761 | ||
| Prognostic value of intratumoral natural killer cells in gastric carcinoma | Q73388437 | ||
| Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis | Q73572644 | ||
| The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients | Q36946671 | ||
| Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice | Q37120772 | ||
| Adaptive immune features of natural killer cells | Q37172503 | ||
| Expansion of highly cytotoxic human natural killer cells for cancer cell therapy | Q37277554 | ||
| Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer | Q37370451 | ||
| Novel anti-EPHA2 antibody, DS-8895a for cancer treatment | Q37473163 | ||
| Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma | Q37557880 | ||
| Human fused NKG2D-IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells | Q37714638 | ||
| Promotion of cell proliferation and inhibition of ADCC by cancerous immunoglobulin expressed in cancer cell lines | Q37729143 | ||
| Protein-bound polysaccharide K and interleukin-2 regulate different nuclear transcription factors in the NKL human natural killer cell line. | Q38298879 | ||
| Immune checkpoint blockade in hematologic malignancies | Q38400922 | ||
| Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy | Q38666579 | ||
| Optimization of human NK cell manufacturing: Fully-automated separation, improved ex vivo expansion using IL-21 with autologous feeder cells and generation of anti-CD123-CAR-expressing effector cells | Q38694856 | ||
| DKK3 attenuates the cytotoxic effect of natural killer cells on CD133+ gastric cancer cells | Q38715677 | ||
| Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma | Q38728945 | ||
| In Vitro Generation of Human NK Cells Expressing Chimeric Antigen Receptor Through Differentiation of Gene-Modified Hematopoietic Stem Cells | Q38771094 | ||
| Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial | Q38829062 | ||
| Copy number variations of HLA-I and activation of NKp30 pathway determine the sensitivity of gastric cancer cells to the cytotoxicity of natural killer cells | Q38835740 | ||
| Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma | Q38907104 | ||
| A polysaccharide from Salvia miltiorrhiza Bunge improves immune function in gastric cancer rats | Q38974224 | ||
| Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. | Q38976993 | ||
| Tumor-Associated Monocytes/Macrophages Impair NK-Cell Function via TGFβ1 in Human Gastric Cancer | Q38985857 | ||
| Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer | Q39016695 | ||
| Markers and function of human NK cells in normal and pathological conditions | Q39068084 | ||
| The enhanced effect of lupeol on the destruction of gastric cancer cells by NK cells | Q39157112 | ||
| Role of Distinct Natural Killer Cell Subsets in Anticancer Response | Q39210022 | ||
| NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation | Q39236283 | ||
| Midkine upregulates MICA/B expression in human gastric cancer cells and decreases natural killer cell cytotoxicity | Q39380204 | ||
| Engineering Natural Killer Cells for Cancer Immunotherapy | Q39408704 | ||
| NK Cell Exhaustion. | Q39431541 | ||
| Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity | Q39645776 | ||
| Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity | Q39990738 | ||
| SMAD4 impedes the conversion of NK cells into ILC1-like cells by curtailing non-canonical TGF-β signaling | Q40101474 | ||
| Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. | Q40113311 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | stomach neoplasm | Q4335552 |
| adoptive immunotherapy | Q72138716 | ||
| P304 | page(s) | 3095 | |
| P577 | publication date | 2018-01-01 | |
| 2019-01-21 | |||
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Therapeutic Potential of Natural Killer Cells in Gastric Cancer | |
| P478 | volume | 9 |
Search more.